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Abstract
Objective: Insulin resistance (IR), a reduced physiological response of peripheral tissues to the action of insulin, is one 
of the major causes of type 2 diabetes. We sought to evaluate the relationship between serum C-reactive protein (CRP), 
a marker of systemic inflammation, and prevalence of IR among Peruvian adults.
Methods: This population based study of 1,525 individuals (569 men and 956 women; mean age 39 years old) was 
conducted among residents in Lima and Callao, Peru. Fasting plasma glucose, insulin, and CRP concentrations were 
measured using standard approaches. Insulin resistance was assessed using the homeostasis model (HOMA-IR). 
Categories of CRP were defined by the following tertiles: <0.81 mg/l, 0.81-2.53 mg/l, and >2.53 mg/l. Logistic regression 
procedures were employed to estimate odds ratios (OR) and 95% confidence intervals (CI).
Results: Elevated CRP were significantly associated with increased mean fasting insulin and mean HOMA-IR 
concentrations (p < 0.001). Women with CRP concentration >2.53 mg/l (upper tertile) had a 2.18-fold increased risk of 
IR (OR = 2.18 95% CI 1.51-3.16) as compared with those in the lowest tertile (<0.81 mg/l). Among men, those in the 
upper tertile had a 2.54-fold increased risk of IR (OR = 2.54 95% CI 1.54-4.20) as compared with those in the lowest 
tertile.
Conclusion: Our observations among Peruvians suggest that chronic systemic inflammation, as evidenced by 
elevated CRP, may be of etiologic importance in insulin resistance and diabetes.
Background
Insulin resistance (IR), a reduced physiological response
of peripheral tissues to the action of insulin, is one of the
major causes of type 2 diabetes and plays a critical role in
the pathogenesis of cardiovascular diseases (CVDs) [1].
Recent studies have shown that the worldwide prevalence
of IR and its associated risk factors have increased mark-
edly [2,3]. IR is believed to be associated with chronic
inflammatory response which is characterized by abnor-
mal cytokine production and the activations of pro-
inflammatory signaling pathways [4,5].
The systemic inflammatory biomarker C-reactive pro-
tein (CRP) when measured in the blood with high sensi-
tivity assay has been reported to be a strong and
independent predictor of myocardial infarction, ischemic
stroke, type 2 diabetes, and hypertension [6,7]. Several
studies have provided strong evidence of association
between CRP and CVD risk independent of traditional
risk factors, such as cholesterol, blood pressure, alcohol
consumption, and smoking habit [7,8]. Accumulating
experimental and epidemiologic data now link inflamma-
tory processes to impaired glucose metabolism [9]. It has
also been reported that elevated CRP concentrations may
reflect not only local inflammation at atherosclerotic
lesions but also predict future CVD risk including IR
[7,10].
An emerging body of evidence documents associations
of elevated CRP concentrations in individuals with IR
[10-13]. Few studies, however, have evaluated this associ-
ation among South Americans. We, therefore, sought to
evaluate the relationship between IR and serum CRP
among Peruvian adults. Elucidation of the relationship
between IR and CRP concentration may lead to an
improved recognition of individuals at risk for future dia-* Correspondence: mirt@u.washington.edu1 University of Washington, Multidisciplinary International Research Training 
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novel therapeutic targets [9].
Methods
This study is part of a larger population based study
among Peruvian men and women who participated in the
Prevalencia de Factores de Riesgo de Enfermedades No-
Transmissibles (Prevalence of Risk Factors for Non
Transmissible Diseases) referred to as the FRENT study.
The primary objective of the FRENT study was to deter-
mine the prevalence and risk factors associated to non-
transmissible diseases among residents in Lima and Cal-
lao, Peru.
Details of the study setting, sampling, and data collec-
tion procedures have been described previously [14]. For
the study described here, we excluded subjects with dia-
betes (69), those who were taking lipid lowering drugs
(33), and with missing laboratory information (31). The
final analyzed sample included 1,525 individuals (569
men and 956 women).
Data Collection and Variable Specification
Briefly, each participant was interviewed by a trained
interviewer using a structured questionnaire validated by
the Pan American Health Organization (PAHO) for
assessing the prevalence of non transmissible disease
(NTD) risk factors [15]. The questionnaire inquired
about individuals' age, gender, educational attainment,
and medical history via in-person interviews. Height and
weight were measured with participants wearing light
clothing and no shoes. Waist circumference was mea-
sured from the midpoint between the iliac crest and the
lower ribs measured at the sides. Hip circumference was
measured at the point of the maximum circumference
over the buttocks. After participants had been seated for
at least 5 minutes, and again after 30 minutes during the
interview, a resting blood pressure was measured using a
Mercury Desk Sphygmomanometer, these two values
were averaged. A follow-up visit to participants' home
was made the next morning to collect a blood sample
after a 12-hour fast. Aliquots of serum were used to
determine participants' fasting glucose concentrations
and lipid profiles. Serum triglycerides (TG), total choles-
terol, high-density lipoprotein cholesterol (HDL-C), low-
density lipoprotein cholesterol (LDL-C), glucose, and
insulin were measured at the Peruvian National Institute
of Health Laboratory in Lima, Peru. TG concentrations
were determined by standardized enzymatic procedures
using glycerol phosphate oxidase assay. HDL-C was mea-
sured by a chemical precipitation technique using dex-
tran sulfate. Participants' fasting serum glucose (FSG)
was determined using standardized glucose oxidase
method (glucose oxidase GOD-PAP).
As an index of insulin resistance, we determined the
Homeostatis Model Assessment of Insulin Resistance
(HOMA-IR) index by dividing the product of fasting glu-
cose (mg/dl) and fasting insulin (μIU/ml) by 405 [16]. The
HOMA IR is widely used in clinical trials and has been
shown to be correlated with the results obtained from the
"gold standard" euglycemic glucose clamp method [1].
Serum CRP concentrations were measured by an ultra-
sensitive competitive immunoassay (Dade Behring, Deer-
field, Illinois) with the intra- and inter-assay coefficients
of variation both < 10% [17]. All laboratory assays were
completed without knowledge of participants' medical
history.
All subjects provided informed consent and all research
protocols were approved by the Institutional Review
Boards of National Institute of Health in Peru, Dos de
Mayo Hospital, Peru and the Human Subjects Division at
the University of Washington, USA.
Statistical Analyses
We first explored frequency distributions of socio-demo-
graphic, clinical and behavioral characteristics of sub-
jects. Continuous variables were expressed as mean ±
standard error of means (SEM). Categorical variables
were expressed as number (percent, %). Chi-Square tests
were used to evaluate differences in the distribution of
categorical variables. Student's t tests were used to evalu-
ate differences in mean distributions. Associations of
CRP with HOMA-IR and other continuous covariates
(e.g., insulin and glucose) were determined using the
Pearson's correlation coefficients. The distribution of
fasting insulin, fasting glucose, and HOMA-IR were
skewed to the right side, and the values were transformed
to the natural logarithms in the analysis. Thus, the pre-
sented means were always geometric means. Mean values
of fasting insulin, fasting glucose, and HOMA-IR were
compared across the different concentrations of CRP
using linear regression procedures. Categories of CRP
were defined by the following tertiles: <0.81 mg/l, 0.81-
2.53 mg/l, and >2.53 mg/l. The group with the lowest ter-
tile of CRP (<0.81) served as the reference group. Con-
founding variables were considered a priori on the basis
of their hypothesized relationship with IR and CRP. Mul-
tiple linear regression procedures were used to adjust for
covariates of interest: age, BMI, and current smoking sta-
tus. Presence of IR (yes/no) was defined as being in the
highest quartile of HOMA-IR (>5.12). Logistic regression
procedures were employed to estimate odds ratios (OR)
and confidence intervals (CI) of IR according to tertiles of
CRP. In multivariate analysis, tests for linear trend across
increasing categories of CRP were conducted by treating
the three-level CRP-concentration variable as an ordinal
variable. Since previous studies have noted that the effect
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analyses were reported for men and women separately.
All statistical analyses were performed using SPSS (ver-
sion 14.0, SPSS Inc. Chicago, IL, USA) software. All
reported p-values are two tailed and confidence intervals
were calculated at the 95% concentration.
Results
Characteristics of study participants according to gender
are shown in Table 1. The percentages of current smok-
ers, mean value of waist circumference, triglycerides, sys-
tolic and diastolic blood pressure were significantly
higher among men than women. Women had signifi-
cantly higher mean age, high density lipoprotein-choles-
terol, total cholesterol, and low density lipoprotein-
cholesterol. There was no significant gender difference in
the values of CRP, fasting insulin and fasting glucose. Val-
ues of CRP were positively associated with fasting insulin
and HOMA-IR in men (r = 0.190 and 0.166 respectively
<0.001) and women (r = 0.157 and 0.153 respectively, p <
0.001).
Table 2 shows the adjusted (age, BMI, current smoking
status) mean values of fasting insulin, fasting glucose, and
HOMA-IR according to categories of serum CRP and
gender. Elevated CRP concentrations were significantly
associated with increased fasting insulin and HOMA-IR
concentrations (trend test p < 0.001). Among women,
there was no observed difference in mean fasting glucose
whereas men had significantly lower fasting glucose with
increased CRP concentrations (trend test p = 0.005).
Serum CRP concentrations were statistically signifi-
cantly and positively associated with prevalent IR in both
women and men in our population (trend test p-values <
0.001) (Table 3). After adjusting for age, smoking status
and body mass index the ORs and 95% confidence inter-
vals across increasing tertiles for women were:, 1.35 (95%
CI 0.91-1.99), and 2.18 (95% CI 1.50-3.17). The corre-
sponding ORs and 95% confidence intervals for men we
as follows: 2.67 (95% CI 1.61-4.44), and 2.58 (95% CI 1.55-
4.28).
Discussion
The present study has shown that IR was associated with
CRP, a marker of systemic inflammation, in the Peruvian
adult population. After adjusting for BMI, age, and cur-
rent smoking status, those in the upper tertile (CRP con-
centration >2.53 mg/l) had more than 2-fold increased
risk of IR, compared with those in lowest tertile (CRP
concentration <0.81 mg/l) in both men and women. Our
observations among Peruvians are in agreement with
reports from cross sectional and prospective studies of
other populations that showed associations between IR
Table 1: Characteristics of the Study Population, Lima, Peru 2006.
Characteristics Women (N = 956) Men (N = 569) **P-Value
Age 39.9 ± 14.5 38.3 ± 15.9
Ever smoking (%) 16.0 44.5 <0.001
Current smoking (%) 9.6 32.0 <0.001
BMI (kg/m2) 26.6 ± 4.8 26.1 ± 4.0 0.042
Waist Circumference (cm) 88.3 ± 11.5 92.0 ± 10.6 <0.001
Hip circumference (cm) 99.6 ± 10.7 98.8 ± 8.4 0.111
Total cholesterol (mg/dl) 186.0 ± 42.0 179.6 ± 39.1 0.003
HDL cholesterol (mg/dl) 48.5 ± 0.4 42.6 ± 0.4 <0.001
LDL cholesterol (mg/dl)† 114 (94-138) 110 (92-135) 0.042
Triglycerides (mg/dl)† 104(69.0-156.0) 124(84.0-188.5) <0.001
Systolic blood pressure (mm Hg) 113.4 ± 16.1 119.9 ± 13.8 <0.001
Diastolic blood pressure (mm Hg) 71.5 ± 10.4 75.5 ± 10.6 <0.001
CRP (mg/l)† 1.5 (0.6-3.4) 1.5 (0.6-3.8) 0.252
Fasting insulin(μU/ml)† 15.0 (10.2-22.8) 16.0 (10.6-23.9) 0.319
Fasting glucose(mmol/l) 4.8 ± 1.0 4.9 ± 1.1 0.180
HOMA-IR† 3.1 (2.1-4.9) 3.4 (2.2-5.3) 0.167
* Data are mean ± SD, percentages or median (interquartile range) for variables with skewed distributions †Test of significance was based on 
log-transformed values
** P-value from Chi-Square test for categorical variables or from Student's t-test for continuous variables
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ferent possible mechanisms.
A number of studies have reported that low-grade
inflammation is a novel risk factor in all stages of athero-
sclerosis and acute coronary syndrome [18,19]. It appears
that adipose tissue in general; visceral adipose tissue in
particular, plays a key role in regulating inflammation
[10]. Notably, CRP is primary synthesized in the liver and
regulated by the pro-inflammatory cytokine IL-6 and
tumor necrosis factor-alpha (TNF-α) [20] in adiposities.
This in part suggests that the associations of CRP con-
centrations with fasting insulin, fasting glucose, and
Table 2: *Adjusted Geometric Mean Values of Fasting Insulin, Fasting Glucose, and HOMA-IR, According to C-Reactive 
Protein Concentration and Gender.
C-Reactive Protein (mg/l) n Geometric Mean of 
fasting insulin (μU/ml) 
(95% CI)
Geometric Mean of 
fasting glucose 
(mmol/l) (95% CI)
Geometric Mean of 
HOMA-IR†(95% CI)
Women
<0.81 325 2.63 (2.56-2.69) 1.56 (1.55-1.58) 1.08 (1.01-1.15)
0.81-2.53 320 2.76 (2.72-2.81) 1.56 (1.55-1.57) 1.21 (1.17-1.26)
>2.53 310 2.90 (2.83-2.97) 1.56 (1.54-1.57) 1.35 (1.27-1.43)
Trend p-value <0.001 0.593 <0.001
Men
<0.81 183 2.59 (2.50-2.68) 1.60 (1.58-1.62) 1.08 (0.99-1.17)
0.81-2.53 189 2.77 (2.71-2.82) 1.58 (1.56-1.59) 1.23 (1.17-1.29)
>2.53 197 2.94 (2.85-3.02) 1.55 (1.54-1.58) 1.38(1.29-1.47)
Trend p-value <0.001 0.005 <0.001
† HOMA-IR-Homeostasis model assessment of insulin resistance.
*Mean values were adjusted for age, current cigarette smoking status, and body mass index. Separate models were estimated for women and 
men.
Table 3: Adjusted Odds Ratios (OR) and 95% Confidence Intervals (95% CI) of Insulin Resistance among Peruvian Women 
and Men According to Tertiles of Serum CRP Concentrations.
Insulin Resistance
C-Reactive Protein (mg/l) No n (%) Yes n (%) *Adjusted Odds Ratio (95% CI)
All
<0.81 422 (36.9) 86 (22.6) 1.00 (Reference)
0.81-2.53 376 (32.9) 133 (34.9) 1.75 (1.28-2.35)
>2.53 346 (30.2) 162 (42.5) 2.29 (1.70-3.09)
Trend p-value <0.001
Women
<0.81 267 (36.7) 58 (25.3) 1.00 (Reference)
0.81-2.53 249 (34.3) 71 (31.0) 1.35 (0.91-1.99)
>2.53 211 (29.0) 100 (43.7) 2.18 (1.50-3.17)
Trend p-value <0.001
Men
<0.81 155 (37.2) 28 (18.4) 1.00 (Reference)
0.81-2.53 127 (30.5) 62 (40.8) 2.67 (1.61-4.44)
>2.53 135 (32.4) 62 (40.8) 2.58 (1.55-4.28)
Trend p-value 0.001
*Adjusted for age, current cigarette smoking status, and body mass index. Separate models were estimated for women and men.
Gelaye et al. Diabetology & Metabolic Syndrome 2010, 2:30
http://www.dmsjournal.com/content/2/1/30
Page 5 of 6HOMA-IR could be due to the presence of a chronic sys-
temic sub-clinical inflammation [10].
It has also been shown that CRP, in addition to provid-
ing downstream integration to overall cytokine activa-
tion, is bound to the membranes of damaged vascular
cells where it activates complement proteins or enhances
the production of thrombogenic agents [21,22] depend-
ing on conventional risk factors and other markers of
inflammation [23]. These instances of vascular inflamma-
tion may contribute to the development of insulin resis-
tance [21,22] although the mechanisms are not fully
known [23].
Some important study limitations must be considered
when interpreting the results of our study. First, because
of this cross-sectional data collection design, we cannot
be certain of the temporal relation between elevated CRP
concentration and risk of insulin resistance. Inferences
concerning the risk for incident insulin resistance and
type 2 diabetes, however, will be enhanced with data from
prospective studies among Peruvians. Second, a single
measurement of serum CRP is not likely to provide a
time-integrated measure of inflammation status. How-
ever, several investigators have noted that CRP concen-
trations are stable over a long period of time [7,24]. Third,
direct measures of central adiposity were not used. Stud-
ies have shown that among middle-aged adults, BMI is
strongly correlated with more invasive direct measures of
central adiposity [25,26]. Fourth, HOMA-IR was used for
assessing insulin resistance in our population-based epi-
demiological study. The euglycemic glucose clamp has
been reported to be the gold standard method for evalu-
ating insulin resistance [16]. Because of its invasiveness,
complexity and expense, the euglycemic glucose clamp
method is of limited use for clinical screening exams and
population-based epidemiological studies. The results
from HOMA-IR have been correlated with the results
obtained from the euglycemic hyperinsulinemic clamp
technique [1,16].
Our understanding of CRP over the last decade has
increased markedly. CRP has been shown to be a useful
marker and mediator of inflammation and a powerful
predictor of future CVD event [9]. This increased recog-
nition has led for the Centers for Disease Control and
Prevention and the American Heart Association to pub-
lish guidelines that endorse the use of CRP as the only
inflammatory biomarker currently available with ade-
quate standardization and predictive value that is suitable
as an adjunct to traditional risk factor screening [27].
Collectively, available evidence suggests that systemic
inflammation, as evidenced by elevated CRP, may be of
etiologic importance in insulin resistance and diabetes.
Our observation among Peruvians raise the possibility
that inflammatory markers, like CRP, might provide an
adjunctive method for early detection of type 2 diabetes
although further investigation is needed to confirm this
observation.
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